Company Profile: Zumutor Biologics
Founded: 2015
Headquarters: Boston, MA, USA (Cambridge Campus)
R&D Laboratory: Bangalore, India
ISO Certification: ISO 9001:2015
Zumutor Biologics is an innovative biotechnology company focusing on the field of immuno-oncology, particularly in NK cell therapeutics. The company has developed the proprietary INABLR™ technology to create therapeutic antibodies that target innate immunity pathways and regulate the tumor microenvironment. Their mission is to revolutionize cancer treatment through advanced NK cell harnessing, promising transformative solutions in the oncology landscape.
Key Executives
- Kavitha Iyer Rodrigues: Co-Founder & CEO
- Location: Bengaluru
- Background: With over 15 years in biotechnology, she holds an MS in Clinical Microbiology from KMC Manipal and an MBA from IIM Bangalore.
- Anirban Bhattacharya: Chief Financial Officer
- Location: Delhi, India
- Experience: Brings over 25 years in business finance, legal, HR, and M&A within the biopharmaceutical sector.
- Maloy Ghosh: Chief Scientific Officer
- Location: Bengaluru, India
- Role: Leads strategic decisions and R&D, previously associated with Theramyt Novobiologics Pvt Ltd.
Funding and Financials
Zumutor Biologics has amassed $28 million in funding from investors including Accel Partners, Bharat Innovation Fund, Siana Capital, Aarin Capital, and KITVEN. A notable $6.2 million funding round was led by Siana Capital, with continuous fundraising efforts since the company's inception in 2013.
Product Pipeline and Clinical Trials
ZM008-001 Trial
Zumutor Biologics has recently commenced a Phase 1 clinical trial for ZM008, targeting the LLT1 pathway crucial for NK cell activation.
- Trial Details:
- Objective: Safety assessment and preliminary antitumor activity.
- Design: Open-label, multicenter, dose-escalation.
- Target Conditions: Non-small cell lung cancer, triple-negative breast cancer, prostate cancer, and other solid tumors.
- Mechanism: Enhancing immune response by converting 'cold' tumors to 'hot'.
Therapy involves ZM008 as monotherapy or in combination with Pembrolizumab, targeting resistance in current immunotherapies. Anticipated trial results and studies will clarify its therapeutic potential.
Strategic Vision and Future Prospects
Zumutor Biologics is dedicated to addressing significant unmet needs in cancer treatment by focusing on a robust portfolio of antibodies. Their continuous R&D and strategic alliances are aimed at creating a lasting impact within the biotech sector, leveraging NK cells to innovate in immune-oncology.
Competitor Profile
Key Competitors
1. AbbVie Inc.
- Global biopharmaceutical company focused on therapies for complex diseases.
2. Astellas Pharma US
- Specialized in diverse therapeutic areas, including oncology.
3. Bristol Myers Squibb
- Innovator in cancer treatment and other severe diseases.
4. UCB Pharma
- Develops medicines in neurology and immunology.
5. Genentech
- Leader in cancer treatment with innovative biotechnology approaches.
6. Fate Therapeutics
- Focuses on cellular immunotherapies for cancer, leveraging stem cell platforms.
7. Nkarta Inc.
- Enhancing allogeneic NK cells, developing off-the-shelf therapies.
8. Modulus Therapeutics
- AI-driven cell therapy company engineering NK cells for solid tumors.
9. ORIC Pharmaceuticals
- Addresses cancer resistance, extending the efficacy of therapies.
10. Imvax Inc.
- Develops personalized immunotherapies targeting solid tumors.
Competitive Landscape
Zumutor Biologics operates within a vibrant biotechnology landscape characterized by diverse cancer treatment methodologies. Their focus on NK cell therapeutics through the INABLR platform positions them competitively against both established pharmaceutical leaders and emergent biotech companies. Competitors range from those harnessing engineered NK cells to others utilizing advanced immunotherapy strategies, each advancing towards more accessible and efficient cancer treatment solutions.
